Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Related Articles
Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL
Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.
Same‐day molecular testing for targetable mutations in solid tumor cytopathology—The next frontier of the rapid on‐site evaluation
This study explores the feasibility of using cytology aspirate smear slides, cell blocks, and small tissue biopsies on an ultra-rapid, cartridge-based polymerase chain reaction assay…
FDA Approvals in Oncology: October-December 2024
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are new to the market.
Celebrating 50 Years of Excellence | Oncology Nursing Society
For five decades, ONS has been at the forefront of advancing oncology nursing, empowering nurses, and driving innovative patient care. As we look back on…
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
MD Anderson and Myriad announced a five-year strategic collaboration to accelerate the clinical evaluation and development of Myriad’s molecular residual disease assay.
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is…
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
DFCI Initiative to Study RAS-Driven Cancers
Boston, MA–based Dana-Farber Cancer Institute (DFCI) today announced the launch of the Center for RAS Therapeutics, an initiative that aims to advance new treatments for…
Erdheim-Chester Disease
Erdheim-Chester disease is a rare condition affecting many parts of the body, it most commonly affects adults.
Blood Global Hematology | American Society of Hematology
Jorge Cortes, MD director of the Georgia Cancer Center at Augusta University and inaugural Editor-in-Chief of Blood Global Hematology, shares his vision for the journal…
